226 related articles for article (PubMed ID: 15736011)
1. Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides.
Blázquez Garrido RM; Espinosa Parra FJ; Alemany Francés L; Ramos Guevara RM; Sánchez-Nieto JM; Segovia Hernández M; Serrano Martínez JA; Huerta FH
Clin Infect Dis; 2005 Mar; 40(6):800-6. PubMed ID: 15736011
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy.
Mykietiuk A; Carratalà J; Fernández-Sabé N; Dorca J; Verdaguer R; Manresa F; Gudiol F
Clin Infect Dis; 2005 Mar; 40(6):794-9. PubMed ID: 15736010
[TBL] [Abstract][Full Text] [Related]
3. Impact of rifampicin addition to clarithromycin in Legionella pneumophila pneumonia.
Grau S; Antonio JM; Ribes E; Salvadó M; Garcés JM; Garau J
Int J Antimicrob Agents; 2006 Sep; 28(3):249-52. PubMed ID: 16870401
[TBL] [Abstract][Full Text] [Related]
4. Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study.
Griffin AT; Peyrani P; Wiemken T; Arnold F
Int J Tuberc Lung Dis; 2010 Apr; 14(4):495-9. PubMed ID: 20202309
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis and treatment of legionella pneumonia].
Ewig S; Tuschy P; Fätkenheuer G
Pneumologie; 2002 Nov; 56(11):695-703. PubMed ID: 12442211
[TBL] [Abstract][Full Text] [Related]
6. Levofloxacin and macrolides for treatment of Legionnaires disease: multiple comparisons give few answers.
Kraus CN; Zalkikar J; Powers JH
Clin Infect Dis; 2005 Aug; 41(3):416; author reply 416-7. PubMed ID: 16007549
[No Abstract] [Full Text] [Related]
7. Role of rifampin-based combination therapy for severe community-acquired Legionella pneumophila pneumonia.
Varner TR; Bookstaver PB; Rudisill CN; Albrecht H
Ann Pharmacother; 2011 Jul; 45(7-8):967-76. PubMed ID: 21775694
[TBL] [Abstract][Full Text] [Related]
8. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
9. Treatment of legionnaires' disease.
Klein NC; Cunha BA
Semin Respir Infect; 1998 Jun; 13(2):140-6. PubMed ID: 9643392
[TBL] [Abstract][Full Text] [Related]
10. [Treatment for Legionnaires' disease. Macrolides or quinolones?].
Falcó V; Molina I; Juste C; Crespo M; Almirante B; Pigrau C; Ferrer A; Bravo C; Palomar M; Pahissa A
Enferm Infecc Microbiol Clin; 2006; 24(6):360-4. PubMed ID: 16792936
[TBL] [Abstract][Full Text] [Related]
11. Legionella: macrolides or quinolones?
Pedro-Botet L; Yu VL
Clin Microbiol Infect; 2006 May; 12 Suppl 3():25-30. PubMed ID: 16669926
[TBL] [Abstract][Full Text] [Related]
12. Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy.
Gacouin A; Le Tulzo Y; Lavoue S; Camus C; Hoff J; Bassen R; Arvieux C; Heurtin C; Thomas R
Intensive Care Med; 2002 Jun; 28(6):686-91. PubMed ID: 12107671
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens.
Dunbar LM; Khashab MM; Kahn JB; Zadeikis N; Xiang JX; Tennenberg AM
Curr Med Res Opin; 2004 Apr; 20(4):555-63. PubMed ID: 15119993
[TBL] [Abstract][Full Text] [Related]
14. Fluoroquinolones vs macrolides in the treatment of Legionnaires disease.
Sabrià M; Pedro-Botet ML; Gómez J; Roig J; Vilaseca B; Sopena N; Baños V;
Chest; 2005 Sep; 128(3):1401-5. PubMed ID: 16162735
[TBL] [Abstract][Full Text] [Related]
15. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization.
Querol-Ribelles JM; Tenías JM; Querol-Borrás JM; Labrador T; Nieto A; González-Granda D; Martínez I
Int J Antimicrob Agents; 2005 Jan; 25(1):75-83. PubMed ID: 15620830
[TBL] [Abstract][Full Text] [Related]
16. Severe community-acquired legionella pneumonia: treatment, complications and outcome.
Hubbard RB; Mathur RM; MacFarlane JT
Q J Med; 1993 May; 86(5):327-32. PubMed ID: 8327650
[TBL] [Abstract][Full Text] [Related]
17. [Choice of antimicrobial therapy for Legionnella infection].
de Vries PA; van der Werf TS; Manson WL; Zijlstra JG
Ned Tijdschr Geneeskd; 2005 Feb; 149(9):452-7. PubMed ID: 15771338
[TBL] [Abstract][Full Text] [Related]
18. Clinical study of an outbreak of Legionnaire's disease in Alcoy, Southeastern Spain.
Fernández JA; López P; Orozco D; Merino J
Eur J Clin Microbiol Infect Dis; 2002 Oct; 21(10):729-35. PubMed ID: 12415472
[TBL] [Abstract][Full Text] [Related]
19. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
[TBL] [Abstract][Full Text] [Related]
20. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
